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Objectives: The purpose of this study is to evaluate the sensitivity and speciﬁcity of free circulating DNA
(FCDNA) as a biomarker in patients suffering from colorectal cancer (CRC), investigating both its prognostic
value correlated with stage of disease and its potential role in early recurrence diagnosis.
Methods: The quantiﬁcation of plasma DNA was achieved through the use of real time quantitative
polymerase chain reaction (PCR) ampliﬁcation of the RNAse P gene. The study enrolled patients undergoing
surgery for primary CRC, at different stages of disease; samples were collected before surgery and during
follow-up examinations every 3 months after surgery. Data were statistically analyzed using Software
Packages SPSS® for Windows.
Results: FCDNAwas detectable in all pre-operative samples and themean valuewas 47.8 ng/mL. FCDNAvalues
increased progressively related to UICC stage of disease, although statistical signiﬁcance was demonstrated
only when comparing patients by pT stage. The analysis of postoperative samples showed a signiﬁcant
decrease of FCDNA quantity after radical surgery and in speciﬁc cases a rise preceding disease recurrence.
Conclusions: This study shows that absolute quantiﬁcation of FCDNA in CRC patients could have a prognostic
value, being related to stage of disease, and could be used as potential tool for early detection of recurrences.
© 2013 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.
1. Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide
and the fourth most common cause of death from cancer. 1,2
Outcomes have improved with advances in surgical technique and
adjuvant therapy. Mortality and survival rates in CRC are highly
inﬂuenced by the stage of the disease at the moment of diagnosis:
5-year survival is excellent for disease localized to the colon (95% for
stage I and 82% for stage II) but decreases to 61% for patients with
regional spread to the lymph nodes (stage III) and to only 8% for
patientswith distantmetastases (stage IV). 3,4 These data conﬁrm that
early diagnosis of the primary tumor as well as the recurrences is
crucial to improve overall and disease free survival.
The most common tumor marker in colorectal cancer is serum
carcinoembryonic antigen (CEA), which is helpful for the detection
of cancer recurrence developing after primary tumor resection;
however, it has relatively poor sensitivity (being elevated in only
about 40% of CRC patients) and speciﬁcity. 5–7
Therefore, during the last few years, there has been an increasing
interest in molecular biomarkers as non-invasive diagnostic tools
for identifying at-risk population and early cancer detection. 8 In
addition, tumor-speciﬁc markers such as KRAS and microsatellite
instability (MSI) are useful for both prognosis and directing chemo-
therapy. 9
Several studies have already reported the presence of FCDNA in
cancer patients’ plasma, showing the same characteristics of primary
tumour DNA such as oncogene expressions, tumour-suppressor gene
mutations, microsatellite and epigenetic alterations. 10 There are
different hypotheses concerning the origin of FCDNA. It may emerge
from tumor necrosis, apoptosis or even active secretion, but the exact
mechanism is unknown. 11 The purpose of this study is to evaluate
FCDNA as a biomarker in patients suffering from colorectal cancer,
investigating both its prognostic value correlatedwith stage of disease
and its potential role in early diagnosis of recurrence.
2. Patients and Methods
All patients who underwent surgical resection of primary colorectal
cancer at the Department of Surgery of the University of Insubria in
Varese were enrolled in the study.
A 3mL sample of peripheral blood was collected in vials containing
EDTA on the day before surgery. Plasma was immediately separated
from the cellular fraction by centrifugation at 3000 rpm for 20min
at 4°C and then stored at −20°C.
300mL of plasma were digested with 100mL of a Proteinase K solu-
tion 20ng/ml in the thermomixer at 58°C. After that, DNA extraction
was performed using BloodPrep™ Chemistry – DNA Isolation from
Fresh and Frozen Whole Blood (Applied Biosystems, Foster City, CA,
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ORIGINAL ARTICLE
E. Cassinotti et al. / International Journal of Surgery 11S1 (2013) S54–S57 S55
Table 1
Variables examined and correlation with FCDNA values
No. of patients % of patients CT (mean±SD) p CFDNA, ng/ml (mean±SD) p
Gender
Female 101 45.3 5.2±3.3 0.793 33.6±64.4 0.254
Male 122 54.7 5.2±3.4 58.8±149.9
Location of tumor
Colon 178 79.8 5.3±3.3 0.003 47.9±111.0 0.027
Rectum 45 20.2 3.8±3.1 78.9±193.8
pT stage
1 19 8.5 5.7±3.6 0.162 15.6±31.4 0.032
2 38 17.1 5.1±3.1 61.8±196.3
3 147 65.9 5.0±3.4 44.8±87.3
4 19 8.5 4.5±3.3 123.1±217.9
pN stage
0 120 53.8 5.1±3.0 0.093 39.3±81.2 0.146
1 65 29.1 5.1±3.9 55.5±158.7
2 38 17.1 4.1±3.0 87.8±173.3
M stage
0 193 86.5 5.3±3.3 0.220 43.0±106.6 0.568
1 30 13.5 4.4±3.4 84.7±197.9
UICC stage
I 43 19.3 5.5±3.3 0.064 25.4±51.8 0.146
II 74 33.2 5.1±3.0 46.5±93.8
III 75 33.6 4.8±3.7 59.4±147.0
IV 31 13.9 4.4±3.4 84.7±197.9
USA) with the ABI PRISM 6100 Nucleic Acid Prepstation (Applied
Biosystems), according to the manufacturer’s instruction, in eight
steps of puriﬁcation, obtaining a ﬁnal elution of 180mL. The DNA was
then stored at −20°C until further analysis.
Quantiﬁcation of circulating free DNA in plasma was performed by
using a real time quantitative PCR approach with ABI Prism® Applied
Biosystems™ 7300 Real-Time PCR System, based on the 5' nucleotide
method. This methodology is based on continuous monitoring of a
progressive ﬂuorogenic PCR by an optical system. We used primers
and ﬂuorogenic probes to speciﬁcally amplify the RNAse P gene.
Each PCR reaction mixture was composed of 10mL of DNA solution,
12.5mL of TaqMan® Universal PCR Master Mix (2x), No AmpErase®
UNG (Applied Biosystems™), 1.25mL of Primer TaqMan® RNase P
and 1.25mL of sterile water. Thermal cycling started with a ﬁrst
incubation step of 50°C for 2min and then a denaturation step
of 95°C for 10min. The thermal proﬁle for the PCR ampliﬁcation
was 95°C for 15 seconds and 60°C for 1 minute. Data obtained
during 45 cycles of ampliﬁcation were analyzed using the Sequence
Detection System software (SDS, Applied Biosystems™) to compare
the ampliﬁcation cycle threshold (CT) of the DNA control sample to
the CT of the unknown experimental samples, obtaining an absolute
quantiﬁcation value. At least three independent quantiﬁcation assays
were performed for each plasma sample.
Data were evaluated with Student’s t-test when comparing two
median values, while ANOVA univariate analysis was performed to
comparemore than two groups. In both cases the level of signiﬁcance
was set at 5% (p < 0.05). Data were statistically analyzed using
Software Packages SPSS® for Windows.
3. Results
3.1. Absolute quantiﬁcation analysis of free circulating plasma DNA in
CRC patients: correlation with stage of disease
Between November 2009 and June 2012, 223 patients admitted
to our department and undergoing colorectal resection for cancer
(122 males, 101 females; mean age 66 years) were enrolled in the
study.
FCDNAwas detectable in all pre-operative samples; themean value
was 47.8 ng/mL (SD 120.6; range: 0–1096.6; median 11.7).
All variables examinated and their correlation with FCDNA values
in ng/mL are reported in Table 1.
The mean FCDNA values for rectal cancer were signiﬁcantly higher
than those for cancer located in the colon (78.9±193.8 vs 47.9±111.0;
p = 0.027, Fig. 1).
Patients were then divided into 4 groups according to UICC stage of
disease (43 patients stage I, 74 patients stage II, 75 patients stage III
and 31 patients stage IV). The mean absolute quantities of CFDNA of
these groups were compared (Fig. 2).
FCDNA quantity increased progressively from stage I to stage IV
with a mean value of 25.4 ng/mL (±51.8) for stage I patients, of
46.5 ng/mL (±93.8) for stage II patients, of 59.4 ng/mL (±147) for
stage III and of 89.7 ng/mL (±197.9) for stage IV patients, although this
did not reach statistical signiﬁcance.
In univariate analysis the pT stage variable was signiﬁcantly related
to increasing CFDNA values (Fig. 3); looking at the pN stage variable,
although FCDNA values increase from pN0 to pN2, statistical analysis
showed signiﬁcance only considering the pN0 versus the pN+ group
(Fig. 4).
3.2. Absolute quantiﬁcation analysis of free circulating plasma DNA in
CRC patients: postoperative values and recurrence diagnosis
The mean value of preoperative FCDNA was compared to the
value obtained from the analysis of samples collected 3 months
after surgery, showing a signiﬁcant decrease: 47.8±120.6 ng/ml vs
12.8±52.4 ng/ml; p =0.019 (Fig. 5).
Furthermore we observed that during follow-up FCDNA quantity
increased in selected patients who developed recurrence, while it
remained low (close to 0ng/ml) in disease-free patients (Figs. 6, 7, 8,
9, 10). In all cases of recurrence FCDNA increased before there was
clinical evidence of disease.
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Fig. 1.Median FCDNA values for rectal vs colon cancer.
Fig. 2. FCDNA values at different UICC stages of disease.
Fig. 3. FCDNA correlated to pT stage of disease.
4. Discussion
The presence of high levels of CFDNA in cancer patients’ plasma
was initially demonstrated by Leon et al. in 1977; this was the ﬁrst
study exploring the clinical potential of circulating nucleic acids as
molecular marker for cancer. 12
FCDNAas a biomarker has several advantages such as the possibility
to be measured by non-invasive techniques, its stability (it appears to
be stable for several years in stored samples of plasma) and a relatively
easy detection.
Nevertheless, the use of CFDNA as a biomarker in colorectal cancer
is not yet ready forwidespread clinical use, as there are large numbers
of genes that can be mutated, and while several methods have been
reported for FCDNAquantiﬁcation, none have been evaluated in terms
Fig. 4. FCDNA correlated to pN stage of disease.
Fig. 5. FCDNA preoperative vs follow-up values.
Fig. 6. FCDNA increasing in disease recurrence.
of reproducibility; for these reasons results from different studies are
not comparable. 13,14
Several studies conﬁrmed that quantiﬁcation of FCDNA could
be a promising biomarker in various cancers, including CRC. 13,14
However, the different methodologies and the lack of standardization
in technique of analysis have hampered the implementation of these
tumour markers in clinical practice.
We previously reported the presence of FCDNA in patients
suffering from CRC, while it was almost undetectable in a cohort
of healthy controls (volunteers with negative colonoscopy). 15 In the
present study, we demonstrated that FCDNA in plasma is related
to location of tumor (higher values in rectal cancer compared to
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Fig. 7. FCDNA increasing in disease recurrence.
Fig. 8. FCDNA increasing in disease recurrence.
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Fig. 9. FCDNA during follow up of a disease-free patient.
colonic localization) and to stage of disease (both to depth of tissue
inﬁltration, pT, and to lymph node invasion, pN).
5. Conclusions
Our data show that pre-operative measurement of FCDNA in CRC
patients contributes to better estimate prognosis because of its
300.00
250.00
200.00
100.00
150.00
50.00
0.00
0 12 24 36
Months
ID 13
C
F
D
N
A
(n
g
/m
l)
Fig. 10. FCDNA during follow up of adisease-free patient.
signiﬁcant correlation with stage of disease; postoperative FCDNA
determination appears to be a potential tool for early detection of
recurrences and might be used as a biomarker in addition to the
clinical/instrumental examination.
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